ESCRS - Supplement: GLAUKOS Istent Inject W Supplement 2022 ;
ESCRS - Supplement: GLAUKOS Istent Inject W Supplement 2022 ;
Supplements

Supplement: GLAUKOS Istent Inject W Supplement 2022

Supplement: GLAUKOS Istent Inject W Supplement 2022

Affecting an estimated 76 million people worldwide in 2020 (1), glaucoma is the leading cause of irreversible vision loss and the second leading cause of blindness worldwide (2). Open angle glau-coma (OAG) is the most common form, occurring in 74% of diagnosed glaucoma cases (3, 4). It is often seen in conjunction with cataract, with approximately one-in-five cataract patients also needing glaucoma medication (5). These numbers present both a daunting challenge and a major opportunity. Elevated intraocular pressure (IOP) remains the major risk factor for glaucoma, and most current treatments, including pharmacological, laser and surgical interventions, focus on lowering IOP (6). Yet each have drawbacks. Ocular hypotensive medications are reasonably safe and effective, but their pressure-reducing effects may wane over time, they can lead to ocular surface disease and conjunctival hyperemia, and adherence is notoriously problematic (7-11). Laser trabeculoplasty reliably reduces IOP but can lose effectiveness after three to five years (38-40) and some forms may induce inflammation in the intermediate term (12). And while incisional surgeries such as trabeculectomy and tube shunt implantation can reduce IOP dra-matically, they expose patients to safety risks, including endophthalmitis and hypotony, that can persist for the lifespan of treatment (13-15).

Tags: glaucoma
Latest Articles
Finding a Keratoconus Consensus

Evolving new consensus should help guide diagnosis and management.

Read more...

Ray of a New Dawn in Corneal Infection Research

Will UVC light the way as a potential treatment for microbial keratitis?

Read more...

Towards a More Inclusive Ophthalmology

The only way to face challenges to inclusivity and equity is to work together without barriers.

Read more...

Glaucoma Treatment Under Pressure

New techniques and technologies add to surgeons’ difficult decisions

Read more...

Outside the Box, Inside the Pipeline

Researchers are tackling glaucoma diagnosis and treatment from all sides.

Read more...

The EHDS Is Ready for the Green Light

If proposal is approved, Europe could see better access to, and exchange and use of, health data.

Read more...

ESCRS to Release Guidelines for Cataract and Refractive Surgery

Comprehensive approach to the safest and most effective modern surgery.

Read more...

Barry Fellowship Opens Up ‘Whole New Field of Thought’

The 2022 recipient combines theoretical and practical to learn new treatments.

Read more...

Digitalising the OR—Experience and Perspectives

Benefits include saving time and improving outcomes.

Read more...

ESCRS Heritage Programme

Visionaries past and present.

Read more...

;